Inflation (US Inflation to 3.3%): Higher inflation can increase operating costs for Aytu BioPharma, including R&D, manufacturing, and administrative expenses. This could compress profit margins if the company cannot fully offset these increases through pricing or efficiency, especially in a regulated industry like pharmaceuticals.

Central Banks Shift to "Higher for Longer" Rates Amid Inflation: Elevated interest rates increase the cost of borrowing for companies. For Aytu BioPharma, which may require capital for ongoing research and development, clinical trials, and commercialization efforts, higher financing costs could impact its ability to fund growth initiatives, manage debt, and ultimately affect profitability.

General Market Sentiment (Q1 2026 Earnings Season): While directly related to banks, the overall sentiment generated by the Q1 2026 earnings season across major US companies can influence investor appetite for risk. A challenging earnings season could lead to a 'risk-off' environment, potentially reducing investor confidence and capital availability for growth-stage pharmaceutical companies like Aytu BioPharma, especially given its history of net losses.